

Product datasheet for **TL301617**

SLC28A1 Human shRNA Plasmid Kit (Locus ID 9154)

Product data:

Product Type:	shRNA Plasmids
Product Name:	SLC28A1 Human shRNA Plasmid Kit (Locus ID 9154)
Locus ID:	9154
Synonyms:	CNT1; HCNT1; URCTU
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	SLC28A1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 9154). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM_001287761 , NM_001287762 , NM_001321721 , NM_001321722 , NM_004213 , NM_201651 , NM_201651.1 , NM_201651.2 , NM_004213.1 , NM_004213.2 , NM_004213.3 , NM_004213.4 , NM_001287761.1 , NM_001287762.1 , BC126204 , BC029788 , BC039898 , BC126206 , BC143908 , NM_001287762.2 , NM_201651.3 , NM_004213.5
UniProt ID:	O00337
Summary:	Sodium-dependent and pyrimidine-selective. Exhibits the transport characteristics of the nucleoside transport system cit or N2 subtype (N2/cit) (selective for pyrimidine nucleosides and adenosine). It also transports the antiviral pyrimidine nucleoside analogs 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC). It may be involved in the intestinal absorption and renal handling of pyrimidine nucleoside analogs used to treat acquired immunodeficiency syndrome (AIDS). It has the following selective inhibition: adenosine, thymidine, cytidine, uridine >> guanosine, inosine.[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).